• 2013 Jan - Specialised Services Commissioning BAD Response

• 2013 Jan - Competition Commission Private Healthcare Market Investigation BAD Response

• 2013 Jan - Malignant melanoma: assessment and management of malignant melanoma

• 2013 Jan - Consultation on the revision of European legislation on medical devices

• 2012 Dec - GMC Shape of Training BAD Response

• 2012 Nov - Psoriasis Engagement

• 2012 Nov - Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma

• 2012 Nov - Electrochemotherapy for metastases (melanoma)

Visit the Parliament.uk website to see the inquiry

• 2012 Oct - House of Commons Health Committee inquiry into the functions of NICE BAD Response

Visit the GOV.UK website to see the review.

• 2012 Oct - Regulation of Cosmetic Interventions BAD Response

Visit the GOV.UK website to see then consultation

• 2012 Sept - Draft Mandate to the NHS Commissioning Board

• 2012 Sept - Depression with a chronic physical health problem

• 2012 Jul - Psoriasis

• 2012 Jul - Vemurafenib for the treatment of unresectable locally advanced or metastatic BRAF V600 mutation positive malignant melanoma

• 2012 May - Referal for suspected cancer

Visit the UK Plan for Rare Diseases Consultation webpage.

• 2012 May - UK Plan for Rare Diseases Consultation BAD Response

• 2012 May - Routes to the BAD and Specialist Register
• 2012 May - Routes to the BAD and Specialist Register BAD Response

• 2012 Jan - Vemurafenib for the treatment of unresectable locally advanced or metastatic BRAFV600 mutation-positive malignant melanoma

• 2011 Nov - Ipilimumab for previously treated advanced (unresectable or metastatic) malignant melanoma

• 2011 Nov - Pressure Ulcers

• 2011 Oct - NICE 150 Quality Standards

• 2011 Oct - Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus

• 2011 Oct - NHS Future Forum - Feedback form

• 2011 Sept - Grisol 1% Spray Solution

• 2011 Aug - HQIP Consultation on Education in Clinical Audit

• 2011 Jul - Savlon Cold Sore Cream

• 2011 Jun - Atopic eczema in children

• 2011 Jun - Vemurafenib for the treatment of locally advanced or metastatic, BRAF V600E mutation-positive malignant melanoma

• 2011 Jun - Ipilimumab for previously treated unresectable malignant melanoma

• 2011 May - Pressure relieving devices

• 2011 May - Pressure Ulcer Management

• 2011 May - Topic Selection

• 2011 Apr - Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus

• 2011 Mar - Ipilimumab for previously treated unresectable malignant melanoma

• 2011 Mar - Golimumab for the treatment of psoriatic arthritis

• 2011 Mar - Ibusol Lotion

• 2011 Mar - Borderline Substances: Information Notes/Application for a Dermatological Product

• 2011 Feb - Bazuka Extra Strength Treatment 26% W/W Gel

• 2011 Jan - Skin Cancer: how the NHS and local authorities can help prevent skin cancer using public information, sun protection resources and by making changes to the environment

• 2011 Jan - Ambulight Photodynamic Therapy for the treatment of non-melanoma skin cancer

• 2011 Jan - Referral for suspected cancer

• 2011 Jan - Prescribing Specials: Five Guiding Principles for Prescribers

• 2010 Dec - Eczema Care Pathway

• 2010 Nov - Acutely ill patients in hospital

• 2010 Oct - Golimumab for the treatment of psoriatic arthritis

• 2010 Oct - Diagnosis and Management of Psoriasis in Young People and Adults

• 2010 Sept - Skin Cancer Prevention

• 2010 Sept - Belimumab for the treatment of active systemic lupus erythematosus

• 2010 Aug - Resources and environmental changes to prevent skin cancer

• 2010 Aug - Etanercept for the treatment of adults with psoriasis; Infliximab for the treatment of psoriasis; Adalimumab for the treatment of psoriasis and Ustekinumab for the treatment of adults with moderate to severe psoriasis

• 2010 Jul - Regaine Scalp Solution

• 2010 Jun - Golimumab for the treatment of psoriatic arthritis

• 2010 Apr - Improving outcomes for people with skin tumours including melanoma (update): The management of low-risk basal cell carcinomas in the community

• 2010 Mar - Guide to the technology appraisal appeals process (review)

• 2010 Feb - Metastatic malignant disease of unknown primary origin

• 2010 Jan - Etanercept, Infliximab and Adalimumab for the treatment of psoriatic arthritis

• 2009 Dec - Improving outcomes for people with skin tumours including melanoma (update): The management of low-risk basal cell carcinomas in the community

• 2009 Aug - Etanercept, Infliximab and Adalimumab for the treatment of psoriatic arthritis

• 2009 Aug - Daktarin Intensiv

• 2009 Jul - Lamisil Once

• 2009 Jun - Ustekinumab for the treatment of moderate to severe psoriaris

• 2009 May - Topic Selection Process for Technology Appraisals

• 2009 May - Alitretinoin for the treatment of chronic eczema of the hand, refractory to steroids

• 2009 Apr - NHS Evidence Accreditation Scheme

• 2009 Apr - Etanercept, infliximab, adalimumab (review) and golimumab for the treatment of psoriatic arthritis

• 2009 Feb - Updates to the Technology Appraisal Processes

• 2009 Jan - Ustekinumab for the treatment of moderate to severe psoriaris

• 2008 Dec - Methods Manual
• 2008 Dec - Process Manual

Review of NICE Technology Appraisal Guidance Nos 103/ 134/ 146; on the use of etanercept and efalizumab for the treatment of adults with psoriasis, infliximab for the treatment of psoriasis and adalimumab for the treatment of psoriasis

• 2008 Dec - Etanercept and Efalizumab for the treatment of adults with psoriasis, Infliximab for the treatment of psoriasis and Adalimumab for the treatment of psoriasis

• 2008 Dec - Alitretinoin for the treatment of chronic eczema of the hand, refractory to steroids

• 2008 Dec - Etanercept for the treatment of moderate to severe plaque psoriasis in children and adolescents

• 2008 Dec - ABT-874 for the treatmentof moderate to severe chronic plaque psoriasis

• 2008 Oct - Ipilimumab for the treatment of malignant melanoma

• 2008 Oct - Dermatology Pharmacists with Special Interests (PhwSI) - revised guidance

• 2008 Oct - Bazuka Treatment Gel

• 2008 Oct - Freederm Gel

• Oct 2008 - Hedrin 4% lotion

• 2008 Sept - Vorinostat for the second line treatment for cutaneous T-cell lymphoma

• 2008 Aug - Dermatology Pharmacists with Special Interests (PhwSI) guidance

• 2008 Jun - Alitretinoin for the treatment of severe chronic hand eczema

• 2008 May - Ustekinumab for the treatment of moderate to severe psoriasis

• 2008 Mar - APPGS Skin Cancer Enquiry: Provision of Cancer Services Across the UK

• 2008 Jan - Lord Darzi's interim report

• 2008 Jan - APPGS commissioning enquiry

• 2007 Oct - Manual for Cancer Services: Consultation pro forma draft skin cancer measures

• 2007 Oct - Using Job Planning and Appraisal to Satisfy Revalidation

• 2007 Oct - Topical negative pressure for wound management

• 2007 Oct Review of Technology Appraisal guidance no. 81: the frequency of application of topical corticosteroids for eczema and Review of NICE Technology Appraisal guidance no. 82; on the use of pimecrolimus and tacrolimus for atopic dermatitis (eczema)

• 2007 Oct - Challenges and Priorities for the MHRA

• 2007 Sept - MLX 342

• 2007 Sept - Infliximab for the treatment of adults with psoriasis

Please note this evidence is similar to that given to NICE in Nov 2006

• 2007 Sept - Adalimumab for the treatment of psoriatic arthritis

• 2007 Aug - Consent: Patients and Doctors Making Decisions Together

• 2007 Jul - Workforce Risk Assessment 2008/09

• 2007 Jul - Atopic Eczema in Chidren second response

• 2007 Jul - Grenz rays therapy for inflammatory skin conditions

• 2007 Jun - Draft guidance on Health in Strategic Environmental Assessment
• 2007 Jun - Draft Guidance on Health in Strategic Environmental Assessment - Consultation Document

• 2007 May - Healthcare Commission's Developing the annual health check 2007/2008

• 2007 May - Commissioning Framework for Health and Well Being

• 2007 Apr - MMC Review Panel

• 2007 Feb - "Developing the Quality and Outcomes" Framework

• 2007 Feb - Programme Methods Guide

• 2007 Jan - Chief Medical Officer's call for radical overhaul of the expert witness programme

• 2006 Dec - European Survey on the information needs of health professionals on allergic diseases

• 2006 Nov - "Standards for HIV Services"

• 2006 Nov - Seeking Views Exercise on Going further on Cancer Waiting Times

• 2006 Oct - The desired dermatology functionality for this initiative

• 2006 May - Selection of Topics for work programme NICE

• 2006 May - Surgical Site Infection

• 2006 Jan - Leflunomide for the treatment of moderate to severe psortiatic arthritis

• 2006 Jan - Adalimumab for the treatment of moderate to severe psoriatic arthritis

• 2005 Dec - Laser Therapy

• 2005 Oct - Fluconazole

• 2005 Sept - Improving Outcomes for People with Skin Tumours including Melanoma

• 2005 Jul - Efalizumab and Etanercept for the treatment of plaque psoriasis response

• 2005 Jul - General Medical Council draft guidance on Management for Doctors

• 2005 Jun - Social Value Judgements

• 2005 May - GMS Quality and Outcomes Framework Review

• 2005 May - Pharmacist Prescribing MHRA-MLX321

• 2005 May - Nurse Prescribing MHRA-MLX320

• 2005 Apr - Improving Outcomes for People with Skin Tumours including Melanoma

• 2004 Dec - MMC Academic Response

• 2001 Sept - Nurse Prescribing MCA Response